Succinic Acid (CID 1110) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(5)
 
 
Inactive(132)
 
 
Inconclusive(5)
 
 
Unspecified(20)
 
 
Top Targets:
P4Hc(4)
 
 
 
Tubulin-bindi..(2)
 
 
NR LBD TR(2)
 
 
NR LBD ROR li..(2)
 
 
RIP(2)
 
 
BioAssay Types:
Literature(82)
 
 
 
 
 
Confirmatory(56)
 
 
 
Screening(5)
 
 
BioActivity Types:
Potency(54)
 
 
 
IC50(7)
 
 
 
Kd(3)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 99    Data Row: 162   Total Pages: 4   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103179217]
IC50 0.0013Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay [AID216185, Type: Literature]
View
2
[SID103179217]
IC50 3Inhibition of 2-oxoglutarate-dependent human recombinant HIF PHD2 preincubated for 1 hr [AID344926, Type: Literature]Egl nine homolog 1 [gi:32129514]
View
3
[SID48416561]
 DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
4
[SID46391683]
 Experimentally measured binding affinity data derived from PDB [AID1811, Type: Literature]Chain A, Aspartate Aminotransferase Mutant Atb17139S142N WITH SUCCINIC ACID [gi:7245555]
View
5
[SID406687]
 NCI In Vivo Anticancer Drug Screen. Data for tumor model B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice [AID194, Type: other]
View
6
[SID103179217]
IC50 85.3Destabilizing effect on human recombinant PHD2 (181-426) expressed in Escherichia coli BL21 (DE3) assessed as half life by limited trypsinolysis/MALDI-MS analysis in presence of ferrous ion [AID349748, Type: Literature]
View
7
[SID103179217]
IC50 85.3Inhibition of human PHD2 at 293K temperature by solvent relaxation technique [AID446353, Type: Literature]Egl nine homolog 1 [gi:32129514]
View
8
[SID103179217]
Kd 100Binding affinity to human PHD2-Mn(II) using 12.5% H2O/87.5% D2O MQC spectrometer operated at 500 MHz at 298K temperature [AID446356, Type: Literature]Egl nine homolog 1 [gi:32129514]
View
9
[SID103179217]
Kd 100Binding affinity to human PHD2 by nondenaturing ESI-MS [AID446352, Type: Literature]Egl nine homolog 1 [gi:32129514]
View
10
[SID103179217]
IC50 320Inhibition of 2-oxoglutarate-dependent human JMJD2E preincubated for 30 mins by FDH coupled assay [AID344918, Type: Literature]
View
11
[SID103179217]
IC50 710Inhibition of 2-oxoglutarate-dependent human JMJD2E in prescence of excess H3K9me3 peptide and 10 uM Fe2 by FDH coupled assay [AID344917, Type: Literature]
View
12
[SID103179217]
Kd 1450Binding affinity to Pyrococcus horikoshii sodium-coupled aspartate transporter [AID328866, Type: Literature]
View
13
[SID103179217]
IC50 10000Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess 2-oxoglutarate and 10 uM Fe2 by FDH coupled assay [AID344916, Type: Literature]
View
14
[SID103179217]
 Inhibition of human recombinant PHD2 (181-426) expressed in Escherichia coli BL21 (DE3) by TR-FRET assay [AID349747, Type: Literature]
View
15
[SID103179217]
 Aqueous solubility [AID19262, Type: Literature]
View
16
[SID103179217]
 Protein interaction energy by using binding affinity towards human L-xylulose reductase enzyme [AID95754, Type: Literature]
View
17
[SID103179217]
 Antileukemic activity of compound against the P-388 lymphocytic leukemic BDF1 male mice at 0.6(mg/kg)/day, administered intraperitoneally; 10.7/9.66 (Treated/control) [AID110255, Type: Literature]
View
18
[SID103179217]
 In vivo antileukemic activity against P-388 lymphocytic leukemia in BDF1 male mice at 60 mg/kg/day intraperitoneal dose expressed as T/C [AID121647, Type: Literature]
View
19
[SID103179217]
 Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset [AID588220, Type: Literature]
View
20
[SID103179217]
Km TP_TRANSPORTER: uptake in Xenopus laevis oocytes [AID681141, Type: other]Solute carrier family 22 member 8 [gi:74730587]
View
21
[SID103179217]
 Activation of human recombinant wild type mitochondrial NADP-ME expressed in Escherichia coli BL21 assessed as one-half maximal activation by spectrophotometry [AID429168, Type: Literature]NADP-dependent malic enzyme, mitochondrial [gi:215274021]
View
22
[SID103179217]
 Hypoglycemic activity in Swiss-Webster mouse assessed as change plasma glucose level at 250 mg/kg, ip after 4 hrs [AID398683, Type: other]
View
23
[SID103179217]
 Toxicity in brine shrimp [AID398684, Type: other]
View
24
[SID103179217]
 Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay [AID447578, Type: Literature]
View
25
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749, Type: Literature]
View
26
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_1, Type: Literature]
View
27
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_2, Type: Literature]
View
28
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_3, Type: Literature]
View
29
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_4, Type: Literature]
View
30
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_5, Type: Literature]
View
31
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_6, Type: Literature]
View
32
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_7, Type: Literature]
View
33
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_8, Type: Literature]
View
34
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_9, Type: Literature]
View
35
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_10, Type: Literature]
View
36
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_11, Type: Literature]
View
37
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_12, Type: Literature]
View
38
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_13, Type: Literature]
View
39
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_14, Type: Literature]
View
40
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_15, Type: Literature]
View
41
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_16, Type: Literature]
View
42
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_17, Type: Literature]
View
43
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_18, Type: Literature]
View
44
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_19, Type: Literature]
View
45
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_20, Type: Literature]
View
46
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_21, Type: Literature]
View
47
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_22, Type: Literature]
View
48
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_23, Type: Literature]
View
49
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_24, Type: Literature]
View
50
[SID29215296]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_25, Type: Literature]
View